Home > Inhibitors & Agonists > JAK/STAT Signaling > JAK
Cat. No. Product name CAS No.
DC21158 JAK3-IN-2 Featured

A potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM.

1443235-95-7
DC11736 PF-956980

A potent, highly specific JAK3 inhibitor with IC50 of 4 nM.

1262832-74-5
DC2096 AG490 Featured

AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively.

133550-30-8
DC7367 AZ-960

AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.

905586-69-8
DC5032 AZD1480

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2.

935666-88-9
DC5064 Baricitinib (INCB28050, LY3009104) Featured

Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2).

1187594-09-7
DC8258 Baricitinib phosphate Featured

Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2).

1187595-84-1
DC4175 BMS-911543

BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively.

1271022-90-2
DC7099 CEP33779 Featured

CEP33779(< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5(pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells.

1257704-57-6
DC7814 Cerdulatinib(PRT-062070; PRT2070)

Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor.

1198300-79-6
DC10341 CHZ868 Featured

CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

1895895-38-1
DC3107 Momelotinib (CYT387,CYT-387) Featured

CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 nM and 18 nM, respectively.

1056634-68-4
DC8171 Decernotinib (VX-509,adelatinib) Featured

Decernotinib(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.

944842-54-0
DC11890 Delgocitinib

Delgocitinib (JTE-052, LEO 124249) is a potent, selective, orally active, pan-JAK inhibitor with IC50 of 2.8, 2.6, 13 and 58 nM for JAK1,2,3 and Tyk2, respectively.

1263774-59-9
DC10826 FM-381 Featured

FM-381 is a JAK3 specific reversible covalent inhibitor with IC50 of 127 pM for JAK3 and demonstrates 400-, 2,700- and 3,600-fold selectivity over JAK1, JAK2, and TYK2, respectively.

DC8375 GLPG0634 analogue Featured

GLPG0634 (analog) is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in the reference patents.

1206101-20-3
DC7137 Filgotinib(GLPG0634) Featured

GPLG0634 is a novel inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.

1206161-97-8
DC12378 Itacitinib(INCB039110) Featured

Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.

1334298-90-6
DC11136 JAK2 inhibitor G5-7

JAK2 inhibitor G5-7 is a small molecule, allosteric JAK2 inhibitor that selectively inhibits JAK2-mediated phosphorylation and activation of EGFR and STAT3 by binding to JAK2.

939681-36-4
DC8077 WHI-P131(Janex 1) Featured

Janex 1 selectively inhibits the tyrosine kinase activity of JAK3 with an IC50 value of 78 µM without affecting the enzymatic activity of JAK1, JAK2, or other protein tyrosine kinases (IC50 ≥350 µM).

202475-60-3
DC7665 Gandotinib(LY2784544)

LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.

1229236-86-5
DC7195 JAK Inhibitor I(Merck 5) Featured

Merck 5 is a potent and reversible ATP-competitive inhibitor of the JAK kinases (JAK1, JAK2, JAK3, and Tyk2). It also blocks IL2 and IL4 dependent proliferation of CTLL cells and inhibits the phosphorylation of STAT5.

457081-03-7
Page 1 / Total 3 FirstPrevNextLastGoto